The Center for Biosimilars® recaps the top stories for the week of December 30, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 30, 2019.
Number 5: A recent study concluded that, for patients who experienced side effects or a loss of response after switching to biosimilar infliximab, a switch back to the reference product was effective.
Number 4: Anti—tumor necrosis factor therapies could play a role in alleviating or even preventing some adverse events related to immune checkpoint inhibition.
Number 3: Recent research shows that many US patients with rheumatoid arthritis who do not respond well to conventional drugs are not advancing to biologic treatment.
Number 2: Clover Biopharmaceuticals announced this week that it has dosed the first patient in a phase 3 clinical study of a proposed etanercept biosimilar.
Number 1: An official working group of the Swiss Society of Gastroenterology has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.